פייסבוק     צור קשר  |   פורום  |   הרשמה לדיוור

 

 

 

 

 


איך את/ה מקבל/ת את הטיפול לגושה
קבלת הטיפול בבית חולים
טיפול בבית בעזרת אחות
טיפול עצמי בעזרת מראה או בני הבית
אני לא מקבל/ת טיפול
הצבע
לרשימת כל הסקרים
קבל/י עידכונים כל פעם שאעדכן את הבלוג שלי בפוסט חדש.

דף הבית>>פרסומים >>הודעה מחברת פרוטליקס 18.8.2011

פרסומים

Protalix BioTherapeutics Announces FDA Accepts for Review Complete Response Resubmission for Taliglucerase Alfa and Assigns PDUFA Date

 

CARMIEL, Israel, Aug. 17, 2011 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE:PLX), announced today that the U.S. Food & Drug Administration (FDA) has accepted for review the resubmission of the taliglucerase alfa New Drug Application (NDA) following the Company's receipt of a Complete Response Letter (CRL) in February 2011.  The FDA deemed the resubmission a class 2, or 6-month, response and established February 1, 2012 as the Prescription Drug User Fee Act (PDUFA) date.  

 

Taliglucerase alfa is the Company's proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD) which is being developed for the treatment of Gaucher disease.

"We look forward to working with the FDA in moving taliglucerase alfa through the regulatory review process over the next few months," stated Dr. David Aviezer, President and CEO of Protalix.  

The Company's submission addresses the questions posed by the FDA in the CRL, including the request for clinical data from the Company's switchover trial and long-term extension trial, and additional information relating to chemistry, manufacturing and controls (CMC).

 

On November 30, 2009, Pfizer and Protalix BioTherapeutics, Inc. entered into an agreement to develop and commercialize taliglucerase alfa.

"Pfizer has worked closely with Protalix to achieve this important milestone," said Diem Nguyen, General Manager, Biosimilars.  "Pfizer is ready to make taliglucerase alfa commercially available to Gaucher patients in the United States, if approved by the FDA."

 

 

Best regards,

 

Shomrat   Shurtz

Director of Lysosomal Therapeutic Products

P r o t a l i x         Biotherapeutics

2  Snunit  Street,  Science    Park

P.O.B 455, Carmiel 20100, Israel

cellular:  + 972 -  52  -  8443344

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

לדף הקודםלדף הבא
RSS